Page 138 - 《中国药房》2023年24期

with long-term administration in Japanese patients with phism and platelet count in infliximab-treated patients[J].
Crohn’s disease：analysis using population pharmacoki‐ Int J Mol Sci，2021，22（11）：6051.
netics[J]. Int J Clin Pharmacol Ther，2020，58（2）：89-102. [36] TERNANT D，BERKANE Z，PICON L，et al. Assessment
[26] FASANMADE A A，ADEDOKUN O J，FORD J，et al. of the influence of inflammation and FCGR3A genotype
Population pharmacokinetic analysis of infliximab in pa‐ on infliximab pharmacokinetics and time to relapse in pa‐
tients with ulcerative colitis[J]. Eur J Clin Pharmacol， tients with Crohn’s disease[J]. Clin Pharmacokinet，2015，
2009，65（12）：1211-1228. 54（5）：551-562.
[27] THOMAS S S，BORAZAN N，BARROSO N，et al. Com‐ [37] SACHS U J，SOCHER I，BRAEUNLICH C G，et al. A
parative immunogenicity of TNF inhibitors：impact on variable number of tandem repeats polymorphism in-
clinical efficacy and tolerability in the management of au‐ fluences the transcriptional activity of the neonatal Fc
toimmune diseases. A systematic review and meta-analysis receptor alpha-chain promoter[J]. Immunology，2006，119
[J]. BioDrugs，2015，29（4）：241-258. （1）：83-89.
[28] HINDRYCKX P，NOVAK G，VANDE CASTEELE N，et [38] BILLIET T，DREESEN E，CLEYNEN I，et al. A genetic
al. Erratum to：incidence，prevention and management of variation in the neonatal Fc-receptor affects anti-TNF
anti-drug antibodies against therapeutic antibodies in in‐ drug concentrations in inflammatory bowel disease[J]. Am
flammatory bowel disease：a practical overview[J]. Drugs， J Gastroenterol，2016，111（10）：1438-1445.
2017，77（4）：379. [39] 彭晓云. LC-MS/MS测定人血清中英夫利昔单抗血药浓
[29] TERNANT D， AUBOURG A， MAGDELAINE- 度方法的建立及临床应用[D]. 广州：华南理工大学，
BEUZELIN C，et al. Infliximab pharmacokinetics in in‐ 2015.
flammatory bowel disease patients[J]. Ther Drug Monit， PENG X Y. Development and validation of LC-MS/MS
2008，30（4）：523-529. method for the quantitation of infliximab in human serum
[30] VAN STAPPEN T，VANDE CASTEELE N，VAN [D]. Guangzhou：South China University of Technology，
ASSCHE G，et al. Clinical relevance of detecting anti- 2015.
infliximab antibodies with a drug-tolerant assay：post hoc [40] 朱扣柱，丁肖梁，陈卫昌，等. 荧光免疫层析法和酶联免
analysis of the TAXIT trial[J]. Gut，2018，67（5）：818-826. 疫吸附法检测英夫利西单抗血药浓度的比较研究[J]. 中
[31] BRANDSE J F，MOULD D，SMEEKES O，et al. A real- 国医院药学杂志，2022，42（24）：2625-2628.
life population pharmacokinetic study reveals factors asso‐ ZHU K Z，DING X L，CHEN W C，et al. Comparison for
ciated with clearance and immunogenicity of infliximab in blood concentration monitoring of infliximab between
inflammatory bowel disease[J]. Inflamm Bowel Dis， fluorescence immunochromatography and enzyme-linked
2017，23（4）：650-660. immunosorbent assay[J]. Chin J Hosp Pharm，2022，42
[32] BAUMAN L E，XIONG Y，MIZUNO T，et al. Improved （24）：2625-2628.
population pharmacokinetic model for predicting opti‐ [41] LEE M W，CONNOR S，NG W，et al. Comparison of in-
mized infliximab exposure in pediatric inflammatory fliximab drug measurement across three commercially
bowel disease[J]. Inflamm Bowel Dis，2020，26（3）： available ELISA kits[J]. Pathology，2016，48（6）：608-612.
429-439. [42] GOROVITS B，BALTRUKONIS D J，BHATTACHARYA
[33] ROOPENIAN D C，AKILESH S. FcRn：the neonatal Fc I，et al. Immunoassay methods used in clinical studies for
receptor comes of age[J]. Nat Rev Immunol，2007，7（9）： the detection of anti-drug antibodies to adalimumab and
715-725. infliximab[J]. Clin Exp Immunol，2018，192（3）：348-365.
[34] XIONG Y，MIZUNO T，COLMAN R，et al. Real-world [43] BERTIN D，SERRERO M，GRIMAUD J C，et al. Moni‐
infliximab pharmacokinetic study informs an electronic toring of infliximab trough levels and anti-infliximab anti‐
health record-embedded dashboard to guide precision do- bodies in inflammatory bowel diseases：a comparison of
sing in children with Crohn’s disease[J]. Clin Pharmacol three commercially available ELISA kits[J]. Cytokine，
Ther，2021，109（6）：1639-1647. 2020，126：154859.
[35] THIBAULT G，PAINTAUD G，SUNG H C，et al. Associa‐ （收稿日期：2023-05-15 修回日期：2023-11-22）
tion of IgG1 antibody clearance with FcγRⅡA polymor‐ （编辑：邹丽娟）

· 3072 · China Pharmacy 2023 Vol. 34 No. 24 中国药房 2023年第34卷第24期